Pharmacokinetic consequences of a citalopram treatment discontinuation

Détails

ID Serval
serval:BIB_F227D75A47EC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Pharmacokinetic consequences of a citalopram treatment discontinuation
Périodique
Therapeutic Drug Monitoring
Auteur(s)
Voirol  P., Rubin  C., Bryois  C., Kosel  M., Buclin  T., Baumann  P.
ISSN
0163-4356 (Print)
Statut éditorial
Publié
Date de publication
06/1999
Volume
21
Numéro
3
Pages
263-6
Notes
Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jun
Résumé
In this pilot study, the pharmacokinetics of citalopram (CIT) were examined in five hospitalized depressed patients after an abrupt discontinuation of a treatment with 40 mg/d of this selective serotonin reuptake inhibitor (SSRI). During the 8-day study period, clinical ratings were regularly carried out. Between days 5 and 8, the patients were treated with clomipramine (75 mg/d). The enantiomers of CIT and its metabolites, demethyl-CIT (DCIT) and CIT-propionic acid derivative (CIT-PROP), were measured repeatedly from day 0 to day 8 by a stereoselective high-performance liquid chromatography (HPLC) procedure. The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.
Mots-clé
Adolescent Adult Aged Antidepressive Agents, Second-Generation/pharmacokinetics/*therapeutic use Citalopram/pharmacokinetics/*therapeutic use Clomipramine/therapeutic use Female Humans Male Middle Aged Serotonin Uptake Inhibitors/pharmacokinetics/*therapeutic use Stereoisomerism *Substance Withdrawal Syndrome
Pubmed
Web of science
Création de la notice
21/01/2008 12:14
Dernière modification de la notice
15/02/2019 18:48
Données d'usage